MicroTransponder
- Industry
- Medical Devices & Instruments
- Founded Year
- 2007
- Headquarters
- Austin, Texas, United States
- Employee Count
- 149
Key People
- Richard Foust - Chief Executive Officer
- Doug Ellison - Chief Commercial Officer
- Navzer Engineer - Chief Scientific Officer and Vice President of Medical Affairs
- Bunker Curnes - Chief Financial Officer
- Jean-Philippe Allar - President, International Markets
- Reema Casavant - Vice President of Research Operations
- Brent Tarver - Vice President of Clinical Affairs
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises seasoned executives with extensive experience in the medical device industry.
The presence of multiple successful MedTech entrepreneurs in the leadership team provides a strong foundation for strategic decision-making and industry navigation.
- Clinical Need
-
Aspect: Very Strong
Summary: The Vivistim System addresses a significant unmet need in stroke rehabilitation.
By providing a clinically proven method to improve upper limb function, the Vivistim System meets a critical demand in post-stroke care.
- Competition
-
Aspect: First mover
Summary: MicroTransponder is a pioneer in paired vagus nerve stimulation for stroke rehabilitation.
While leading the market offers a competitive edge, it also requires significant effort in educating healthcare providers and patients about the new therapy.
- Technical Challenge
-
Aspect: Moderate
Summary: The development of the Vivistim System involved overcoming moderate technical challenges.
Implementing paired vagus nerve stimulation required integrating neuroscience research with medical device engineering, presenting moderate technical hurdles.
- Patent
-
Aspect: Very Strong
Summary: MicroTransponder holds robust patents protecting its innovative technologies.
The company's comprehensive patent portfolio safeguards its proprietary technologies, deterring potential competitors.
- Financing
-
Aspect: Well-funded
Summary: The company has secured substantial funding through multiple investment rounds.
With over $200 million raised, including a $65 million Series F round in 2025, MicroTransponder is well-positioned financially to advance its market presence.
- Regulatory
-
Aspect: 510k/PMA + Reimbursement
Summary: The Vivistim System has received FDA approval and reimbursement coverage.
Obtaining FDA approval and securing reimbursement are critical milestones that enhance the device's accessibility to patients and healthcare providers.
Opportunity Rollup
- Odds of Success
- 3.35
- Peak Market Share
- 4.15
- Segment CAGR
- 4.9%
- Market Segment
- Neurology Devices
- Market Sub Segment
- Neurostimulation Devices
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.21 |
| 2 | 0.62 |
| 3 | 1.45 |
| 4 | 2.90 |
| 5 | 4.15 |
Key Takeaway
MicroTransponder's Vivistim System addresses a critical need in stroke rehabilitation, supported by strong leadership, robust funding, and favorable industry trends, positioning the company for significant market impact.